



22 December 2025

cyclomedica
technegas

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

Technegas® Approved in Colombia – Global Reach Now at 67 Countries

Cyclopharm Limited (ASX: CYC) is pleased to announce that Technegas® has received regulatory approval in Colombia, expanding the number of countries in which Technegas is approved for clinical use to 67 worldwide.

This approval expands Cyclopharm's global presence in functional lung imaging and supports the Company's strategy of increasing access along with expanding the use of true functional ventilation imaging that enables clinicians leveraging artificial intelligence (AI) enabled platforms to directly visualise and measure where oxygen is delivered within the lungs.

Clear Clinical Differentiation

Technegas provides high-resolution ventilation imaging at the site where oxygen is taken up and delivers a direct and functionally accurate assessment of regional lung function. Importantly, Technegas achieves this with a radiation dose that is orders of magnitude lower than that of diagnostic CT imaging, supporting improved patient safety while delivering validated clinical outcomes.

Technegas is supported by hundreds of peer reviewed journal publications, millions of patient procedures and is widely established in pulmonary embolism diagnosis as evidenced by its inclusion by name in internationally endorsed clinical guidelines.

Expanding Applications and AI-Enabled Adoption

The Company is seeing the use of Technegas expand into broader respiratory applications, including COPD, asthma, lung transplantation, and functional lung mapping for surgical and radiotherapy planning. This expansion is being accelerated by advances in AI enabled post-processing and analytics, which enhance quantification of ventilation patterns and enable more precise, personalised evaluation of lung function.

Strategic and Timing Significance

Managing Director James McBrayer commented "The approval of Technegas in Colombia is particularly timely, with the World Federation of Nuclear Medicine and Biology (WFNMB) Congress scheduled to be held in Cartagena, Colombia, in early February 2026. The WFNMB Congress represents a major global forum at which the international nuclear medicine community will converge, providing an important opportunity to showcase advances in AI enabled functional lung imaging and to engage with leading clinicians and researchers, along with industry leaders, from around the world."

Cyclopharm will work with local partners and key clinical centres in Colombia to support education and clinical adoption following this regulatory approval.

ENDS

This ASX announcement was authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary Cyclopharm
Limited
T: +61 (02) 9541 0411

Cyclopharm Limited

Cyclopharm is an ASX-listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas used in functional lung ventilation imaging.

Technegas

The Technegas technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro-furnaced for a few seconds at around 2,700 °C. The resultant gas-like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas, together with advancements in complementary technology, multimodality imaging, and analytical software, is being utilised in other disease states, including COPD, asthma, pulmonary hypertension, and certain interventional applications, such as lobectomies in lung cancer and lung volume reduction surgery.